0.3513 USD
+0.06 (+21.14%)
Overall CANF gets a fundamental rating of 3 out of 10. We evaluated CANF against 533 industry peers in the Biotechnology industry. While CANF seems to be doing ok healthwise, there are quite some concerns on its profitability. CANF has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year CANF has reported negative net income.
In the past year CANF has reported a negative cash flow from operations.
In the past 5 years CANF always reported negative net income.
In the past 5 years CANF always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -102.07%, CANF is doing worse than 75.23% of the companies in the same industry.
Looking at the Return On Equity, with a value of -188.34%, CANF is doing worse than 65.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -102.07% | ||
| ROE | -188.34% | ||
| ROIC | N/A |
ROA(3y)-90.8%
ROA(5y)-101.33%
ROE(3y)-164.91%
ROE(5y)-170%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CANF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CANF does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CANF has more shares outstanding
The number of shares outstanding for CANF has been increased compared to 5 years ago.
CANF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CANF has an Altman-Z score of -32.74. This is a bad value and indicates that CANF is not financially healthy and even has some risk of bankruptcy.
CANF has a Altman-Z score of -32.74. This is amonst the worse of the industry: CANF underperforms 89.68% of its industry peers.
CANF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -32.74 |
ROIC/WACCN/A
WACC8.61%
2.3 Liquidity
CANF has a Current Ratio of 3.60. This indicates that CANF is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CANF (3.60) is comparable to the rest of the industry.
CANF has a Quick Ratio of 3.60. This indicates that CANF is financially healthy and has no problem in meeting its short term obligations.
CANF has a Quick ratio (3.60) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.6 | ||
| Quick Ratio | 3.6 |
3. Growth
3.1 Past
CANF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.00%, which is quite impressive.
CANF shows a decrease in Revenue. In the last year, the revenue decreased by -9.29%.
The Revenue for CANF have been decreasing by -19.81% on average. This is quite bad
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)-9.29%
Revenue growth 3Y-7.55%
Revenue growth 5Y-19.81%
Sales Q2Q%-36.08%
3.2 Future
CANF is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 50.44% yearly.
CANF is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 203.73% yearly.
EPS Next Y13.95%
EPS Next 2Y50.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y-10.92%
Revenue Next 3Y203.73%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CANF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 0.00, the valuation of CANF can be described as very cheap.
CANF's Price/Forward Earnings ratio is rather cheap when compared to the industry. CANF is cheaper than 100.00% of the companies in the same industry.
CANF's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 0 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CANF's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CANF's earnings are expected to grow with 50.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.44%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CANF does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSEARCA:CANF (11/24/2025, 2:12:06 PM)
0.3513
+0.06 (+21.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners3.34%
Inst Owner Change70.01%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap6.00M
Revenue(TTM)674.00K
Net Income(TTM)-7.88M
Analysts82.86
Price Target4.19 (1092.71%)
Short Float %0.3%
Short Ratio0.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-34.33%
PT rev (3m)-37.49%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-22.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 0 | ||
| P/S | 8.9 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.43 | ||
| P/tB | 1.43 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.72
EYN/A
EPS(NY)256.84
Fwd EY73111.01%
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.04
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -102.07% | ||
| ROE | -188.34% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-90.8%
ROA(5y)-101.33%
ROE(3y)-164.91%
ROE(5y)-170%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 6.9% | ||
| Cap/Sales | 0.3% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.6 | ||
| Quick Ratio | 3.6 | ||
| Altman-Z | -32.74 |
F-Score3
WACC8.61%
ROIC/WACCN/A
Cap/Depr(3y)49.68%
Cap/Depr(5y)88.86%
Cap/Sales(3y)0.71%
Cap/Sales(5y)1.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y13.95%
EPS Next 2Y50.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-9.29%
Revenue growth 3Y-7.55%
Revenue growth 5Y-19.81%
Sales Q2Q%-36.08%
Revenue Next Year0%
Revenue Next 2Y-10.92%
Revenue Next 3Y203.73%
Revenue Next 5YN/A
EBIT growth 1Y0.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.49%
OCF growth 3YN/A
OCF growth 5YN/A
CAN FITE BIOPHARMA LTD-ADR / CANF FAQ
Can you provide the ChartMill fundamental rating for CAN FITE BIOPHARMA LTD-ADR?
ChartMill assigns a fundamental rating of 3 / 10 to CANF.
Can you provide the valuation status for CAN FITE BIOPHARMA LTD-ADR?
ChartMill assigns a valuation rating of 4 / 10 to CAN FITE BIOPHARMA LTD-ADR (CANF). This can be considered as Fairly Valued.
Can you provide the profitability details for CAN FITE BIOPHARMA LTD-ADR?
CAN FITE BIOPHARMA LTD-ADR (CANF) has a profitability rating of 0 / 10.
What is the expected EPS growth for CAN FITE BIOPHARMA LTD-ADR (CANF) stock?
The Earnings per Share (EPS) of CAN FITE BIOPHARMA LTD-ADR (CANF) is expected to grow by 13.95% in the next year.